Abstract
Background: the assessment of the safety and efficacy of β2–agonists (BAs) and corticosteroids (CS) is a cornerstone in the management of patients with COPD and bronchial asthma (BA).
Aims and objectives: we determined a number of hemodynamic and cardiac parameters for assessment of effects of ΒΑs and CSs on cardiovascular and bronchopulmonary systems.
Methods: magnetocardiographic (MCG) examinations were performed in 65 patients with COPD (aged 45-75 years) and in 15 with BA (aged 40-70 years) at rest and during pharmacological test (PT) with a single-dose inhalation of: a short acting BA, combined long acting BA with CS and separately with CS. We compared the number of MCG parameters (before and during the PT) reflecting: the levels of pulmonary artery pressure (PAP) and peripheral vascular resistance (PVR), severity of mitral (MR) and/or tricuspidal regurgitation (TR), global coronary (GCorR) and contractile (GConR) reserves of the ventricles, the levels of ischemia of the left ventricle (LVMI).
Results: the beneficial responses to the PT were accompanied by: the decrease in the levels of PAP, PVR and severity of MR and/or TR; the increase in the GCorR and GConR of the ventricles leading to the decrease in the level of LVMI. The adverse systemic effects during the PT were accompanied by: the increase in the levels of PAP, PVR and severity of MR and/or TR; the decrease in the GCorR and GConR leading to the increase in the level of LVMI.
Conclusion: MCG method demonstrated a novel approach to an individual drug dosage adjustment of ΒΑs and CSs for the risk to benefit ratio reduction in patients with COPD and BA.